Abstract
ABSTRACTIn a hollow-fiber model, we mimicked the drug exposures achieved in the lungs of humans treated with standard amikacin, clarithromycin, and cefoxitin combination therapy forMycobacterium abscessusinfection. At optimal dosing, a kill rate of −0.09 (95% confidence interval, −0.04 to 0.03) log10CFU per ml/day was achieved over the first 14 days, after which there was regrowth due to acquired drug resistance. Thus, the standard regimen quickly failed. A new regimen is needed.
Funder
HHS | National Institutes of Health (NIH)
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference16 articles.
1. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases;ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Diseases Society of America;Am J Respir Crit Care Med,2007
2. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease;Clin Infect Dis,2011
3. Amikacin pharmacokinetics/pharmacodynamics in a novel hollow-fiber Mycobacterium abscessus disease model;Antimicrob Agents Chemother,2015
4. Moxifloxacin's limited efficacy in the hollow-fiber model of Mycobacterium abscessus disease;Antimicrob Agents Chemother,2016
5. Susceptibility testing of mycobacteria, Nocardiae and other aerobic actinomycetes;Clinical and Laboratory Standards Institute,2011
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献